

## **Disclosure/Conflict of Interest Statement**


As a provider jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity, and scientific rigor in all of their directly provided or jointly provided/co-provided educational activities. Planners, presenters, and other contributors, in a position to control the content are required to disclose to the audience all relevant financial relationships he/she may have, occurring within the past 24 months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the contributor should disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in health care and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the education activity.

ACCF assesses conflicts of interest (COI) with its faculty, planners, managers, staff, and other individuals who are in a position to control the content of certified activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup (ACWG) through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations.

ACCF has taken the necessary steps to ensure that all relevant financial relationships have been mitigated.

Please note ACCF staff and the ACWG members involved with this activity have nothing to disclose.



## Course Chairs

**Ana Barac MD, PhD, FACC**  
Inova Health Systems

### [Disclosures](#)

*Data Safety Monitoring Board  
ACI Clinical*

**Bonnie Ky, MD, MSCE, FACC**  
University of Pennsylvania School of Medicine

### [Disclosures](#)

*Consultant Fees/Honoraria  
Cytokinetics; Pfizer; Myovant*

*Research/Research Grants  
Pfizer*

*Speaker's Bureau  
Roche*

## Course Vice-Chair

**Richard Cheng, MD, FACC**  
University of Washington

### [Disclosures](#)

*Nothing to disclose*

## Planning Committee

**Craig J. Beavers, PharmD, FACC**  
Baptist Health System

### [Disclosures](#)

*Nothing to disclose*

**Alicia Morgans, MD, MPH**  
Dana-Farber Cancer Institute

### [Disclosures](#)

*Consultant Fees/Honoraria  
Advanced Accelerator Applications; Astellas  
Pharma US; AstraZeneca Pharmaceuticals; Bayer  
Healthcare Pharmaceuticals; Clovis; Curio; Digital  
Science Press; Exelixis; Janssen Pharmaceuticals,  
Inc; Lantheus; Medscape; Novartis Corporation;  
Pfizer; Sanofi-Aventis; SeaGen; Telix*

*Research/Research Grants  
Bayer Healthcare Pharmaceuticals; Dendreon;  
Myovant*

**Kerry Skurka, RN**  
Cardio-Oncology Nurse/Program Consultant  
ICOS Leadership Workgroup - Center of  
Excellence, Nursing, Education, Advocacy,  
Survivorship

### [Disclosures](#)

*Nothing to disclose*

**Kathleen Zhang, MD, FACC**  
University of Texas Southwestern Medical Center

### [Disclosures](#)

*Consultant Fees/Honoraria  
BridgeBio Inc; Eidos Therapeutics; Pfizer, Inc.*

## Faculty

**Daniel Addison, MD**  
The Ohio State University

### [Disclosures](#)


*Nothing to disclose*

**Lauren A. Baldassarre, MD, FACC**  
Yale School of Medicine

### [Disclosures](#)

*Nothing to disclose*

# ADVANCING THE CARDIOVASCULAR CARE OF THE ONCOLOGY PATIENT



**Cathleen Biga, MSN, RN, FACC**  
Cardiovascular Management of Illinois

[Disclosures](#)

*Nothing to disclose*

**Phillip S. Cuculich, MD**  
Washington University School of Medicine  
in St. Louis

[Disclosures](#)

*Consultant Fees/Honoraria  
Abbott Laboratories; Medtronic; Varian Medical  
Systems*

*Research/Research Grants  
Barnes Jewish Hospital Foundation*

**Jeanne M. DeCara, MD, FACC**  
University of Chicago

[Disclosures](#)

*Nothing to disclose*

**Christina Dieli-Conwright, PhD, MPH**  
Dana-Farber Cancer Institute  
Harvard Medical School

[Disclosures](#)

*Nothing to disclose*

**Matthew J. Ehrhardt, MD, MS**  
St. Jude Children's Research Hospital

[Disclosures](#)

*Nothing to disclose*

**Agnes Y.Y. Lee, MD, MSc**  
University of British Columbia

[Disclosures](#)

*Consultant Fees/Honoraria  
Bayer Healthcare Pharmaceuticals; Bristol Myers  
Squibb Company; Janssen Pharmaceuticals, Inc;  
Leo Pharma; Pfizer*

**Mamas A. Mamas, DPhil, MBBCh**  
Radcliffe Cardiology

[Disclosures](#)

*Consultant Fees/Honoraria  
Amgen Inc; Teruno*

*Research/Research Grants  
Abbott Laboratories*

*Speaker's Bureau  
Daiichi Sankyo*

**Pradeep Natarajan, MD, MMSC, FACC**  
Massachusetts General Hospital

[Disclosures](#)

*Consultant Fees/Honoraria  
Allelica; Apple; AstraZeneca; Blackstone Life  
Sciences; Esperion Therapeutics; Foresite Labs;  
Genentech Inc; GV; Novartis Corporation;  
TenSixteen Bio*

*Research/Research Grants  
Allelica; Amgen Inc; Apple; AstraZeneca  
Pharmaceuticals; Boston Scientific; Novartis  
Corporation*

*Stock  
Preciseli; TenSixteen Bio*

**Kevin Oeffinger, MD**  
Duke University

[Disclosures](#)


*Research/Research Grants  
Grail, LLC*

**Tiffany M. Powell-Wiley, MD, MPH**  
National Heart, Lung, and Blood Institute  
National Institutes of Health

[Disclosures](#)

*Nothing to disclose*

# ADVANCING THE CARDIOVASCULAR CARE OF THE ONCOLOGY PATIENT



**Kerry Reynolds, MD**  
Harvard Medical School  
Massachusetts General Cancer Center

[Disclosures](#)  
*Advisory Board*  
*SAGA Diagnostics*

**Jo E. Rodgers, PharmD**  
UNC Eshelman School of Pharmacy

[Disclosures](#)  
*Nothing to disclose*

**Robert Schwab, MD**  
The Hospital of the University of Pennsylvania

[Disclosures](#)  
*Nothing to disclose*

**Joseph A. Sparano, MD**  
Icahn School of Medicine at Mount Sinai

[Disclosures](#)  
*Consultant Fees/Honoraria*  
*Astra Zeneca*

*Data Safety Monitoring Board*  
*Cytel; Genetech, Inc; Novartis; Pfizer*

**Raymond R. Townsend, MD**  
University of Pennsylvania, Perelman School of  
Medicine

[Disclosures](#)  
*Consultant Fees/Honoraria*  
*BackBeat; BD; Janssen Pharmaceuticals, Inc;*  
*Medtronic*

*Data Safety Monitoring*  
*Cytel*

*Royalty*  
*UpToDate*

**Nicholas Wilcox, MD, MHS**  
University of Pennsylvania

[Disclosures](#)  
*Nothing to disclose*

**Ronald Witteles, MD, FACC**  
Stanford University School of Medicine

[Disclosures](#)  
*Consultant Fees/Honoraria*  
*Alexion; Alnylam; AstraZeneca; Eidos; Ionis;*  
*Janssen Pharmaceuticals, Inc. Novo Nordisk Inc;*  
*Pfizer Inc*

**Jean L. Wright, MD**  
John Hopkins University

[Disclosures](#)  
*Nothing to disclose*

**Han Zhu, MD**  
Stanford University

[Disclosures](#)  
*Nothing to disclose*

## Partner Society Joint Sessions


**Saro Armenian, DO, MPH**  
ASH Joint Session Planning Committee  
City of Hope Comprehensive Cancer Center

[Disclosures](#)  
*Nothing to disclose*

**Anne Blaes, MD**  
ASCO Joint Session Planning Committee & Faculty  
University of Minnesota

[Disclosures](#)  
*Nothing to disclose*

# ADVANCING THE CARDIOVASCULAR CARE OF THE ONCOLOGY PATIENT



**Carla Casulo, MD**

ASH Joint Session Planning Committee  
University of Rochester Medical Center

[Disclosures](#)

*Research/Research Grants*

*Gilead; Genentech, Inc; GenMab; SecuraBio*

**Patrick J. Reagan, MD**

ASH Joint Session Faculty  
University of Rochester Medical Center

[Disclosures](#)

*Consultant Fees/Honoraria*

*Caribou Biosciences; Kite Pharma*